Envarsus XL Immunosuppression Following Liver Transplantation
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The standard immunosuppressive regimen for liver transplantation includes twice daily
tacrolimus (Prograf). In other transplantation models, there are potential benefits to
extended release formulations as lower peak concentrations are thought to have lower rates of
nephrotoxicity. Additionally, compliance with once daily medications is felt to be easier
than twice daily medications. Our aim is to look at our prospective liver transplant group
and see if once daily tacrolimus (Envarsus XR) results in improved renal function as well as
improved health care quality of life.